Cardiome reduces work force by 85%

Monday, July 9, 2012 03:03 PM

Vancouver-based Cardiome Pharma, a research-based biopharmaceutical company, is undertaking a significant work force reduction in response to the recently announced termination of Merck's development efforts relating to the vernakalant oral program.

The workforce reduction eliminates all positions focused on internal research activities along with certain supporting functions. The reduction in personnel will decrease the total number of employees by approximately 85%. The company expects to incur up to $5 million in severance and other charges related to this restructuring over the remainder of the year.

"We very much regret that this decision of the board will affect the individuals that have contributed over the past years to Cardiome," said Dr. William Hunter, interim CEO. "I want to express my appreciation to everyone for their hard work, passion and commitment. We believe this action was necessary to maximize shareholder value by effective management of Cardiome's cash resources and continued focus on our ongoing partnership with Merck on Brinavess IV."

Cariome spreviously announced that one of Hunter's first tasks as interim CEO would be to review all current activities of the company with the immediate objective of optimizing the spend rate. By mid-August, shareholders will be provided with a further progress report via press release and an analyst's conference call.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs